984 research outputs found
Mermis quirindiensis n. sp. (Nematoda : Mermithidae), a parasite of locusts and grasshoppers (Orthoptera : Acrididae) in South-Eastern Australia
Agamermis catadecaudata n. sp. (Nematoda : Mermithidae), a parasitoid of Orthoptera in south-eastern Australia
#Agamermis catadecaudata n. sp. est un parasitoïde des acridiens #Phaulacridium vittatum (Sjöstedt), #Praxibulis exsculptus Rehn et #Brachyexarna lobipennis Sjöstedt, le Tétrigide #Paratettix australicus Walker, du Katydide #Conocephalus sp. et du grillon #Bobilla victoriae Otte & Allexander dans le nord des Tablelands en Nouvelle Galle du Sud. Au laboratoire, #Agamermis catadecaudata n. sp. infeste et se développe sur l'acridien #Chortoicetes terminifera (Walker). #Agamermis catadecaudata n. sp. se distingue de toutes les espèces déjà connues du genre par la longueur des juvéniles infestants et la position du noeud. Ces juvéniles infestants perdent leur queue. Les adultes de #Agamermis catadecaudata n. sp. sont semblables à ceux de #A. decaudata, mais les oeufs sont plus petits et le spicule plus court. Il existe deux types de juvéniles préinfestants dont l'abondance relative est variable. Une espèce non encore décrite, #Agamermis sp. #aff. sinuosa Kaiser, a été rencontrée dans les régions sud, centrale et nord des Tablelands ; elle est sympatrique d'#Agamermis catadecaudata$ n. sp. dans la région nord ; ses hôtes sont inconnus. (Résumé d'auteur
Studies on the genus Amphimermis (Nematoda : Mermithidae) : five new species, including four from Orthoptera in southeastern Australia
Cinq nouvelles espèces d'#Amphimermis sont désignées dont quatre sont décrites : #A. buraki n. sp., parasitoïde de Tettigoniide #Conocephalus sp., #A. acridiorum n. sp., #A; mirabinda n. sp. et #A. australoelegans n. sp., parasitoïdes d'Acridides dont #Phaulacridium vittatum (Sjöstedt), #Oedaleus australis (Saussure) et #Chortoicetes terminifera (Walker), ainsi que, dans le cas d'#A. australoelegans n. sp., le stade larvaire d'un carabe, #Sericesthis sp. Les mâles de #A. buraki n. sp; et de #A. acridiorum n. sp. ressemblent à ceux de #A. avoluta Rubsov & Koval mais en diffèrent par la taille, le type de courbure des spicules et la position des amphides. Les mâles de #A. mirabinda n. sp. ressemblent à ceux de #A. bogongae Welch mais sont plus petits. Les mâles de #A. australoelegans n. sp; ressemblent à ceux de #A. elegans (Hagmeier) et #A. tongaensis (Spiridonov) mais ils sont plus longs dans les deux cas et de plus diffèrent de #A. elegans par la forme de la queue et de #A. tongaensis par la taille des amphides. Les spécimens identifiés par Artyukhovski et Karchenko comme #A. elegans sont considérés comme une nouvelle espèce, #A. artyukhovskii n. sp. Une clé des mâles et une clé des femelles sont proposées dans lesquelles treize espèces déjà décrites sont reconnues valides. Les espèces mises en question sont #A. dolycoris Rubtsov, #A. (?) pardonensis Rubtsov et #A. elongata Rubtsov qui avaient été déclarées #species inquirendae. A. ghilorovi (Polozhentrev & Artyukhovski) est synonymisé à #A. elegans. A. unka sensu Li est considéré comme #nomen dubium$. (Résumé d'auteur
Psammomermis sericesthidis n. sp. (Nematoda : Mermithidae) : a parasitoid of pasture feeding scarab larvae (Coleoptera : Scarabaeidae) in southeastern Australia
#Psammomernis sericesthidis n. sp. est un parasitoïde des larves des scarabés, #Sericesthis geminata Boisduval, #S. nigrolineata (Boisduval) (#Melolonthinae), #Dasygnathus sp., #Anoplognathus sp. (#Rutelinae), #Heteronyx sp. and #Anomalomorpha sp. (#Dynastinae) dans la région des plateaux du sud-est australien. #P. sericesthidis n. sp. se distingue de toutes les espèces décrites dans le genre - sauf #P. aricephala Ipatjeva et Pimenova, 1985 - par la présence d'un seul ergot hypodermique céphalique. #P. sericesthidis n. sp. diffère de #P. aricephala par la forme de la tête, la taille et la position des amphides, et la taille beaucoup plus grande du corps. (Résumé d'auteur
Single Cigarette Sales: State Differences in FDA Advertising and Labeling Violations, 2014, United States
Single cigarettes, which are sold without warning labels and often evade taxes, can serve as a gateway for youth smoking. The Family Smoking Prevention and Tobacco Control Act of 2009 gives the US Food and Drug Administration (FDA) authority to regulate the manufacture, distribution, and marketing of tobacco products, including prohibiting the sale of single cigarettes. To enforce these regulations, the FDA conducted over 335 661 inspections between 2010 and September 30, 2014, and allocated over $115 million toward state inspections contracts
Sensitive electrochemical determination of ethambutol in pharmaceutical formulation and human urine at nickel nanoparticles/electrochemically reduced graphene oxide modified electrode
This paper describes the application of nickel nanoparticles decorated electrochemically reduced
graphene oxide modified glassy carbon electrode (NiNPs/ERGO/GCE) for the determination of ethambutol
(ETB), an anti-Mycobacterium tuberculosis drug. The modified electrode showed remarkable electrocatalytic
properties accompanied with a significant enhancement in the peak current response towards ETB compared to the
bare electrode. The results showed that the composite modified electrode played a significant catalytic role due to
the synergetic effect of NiNPs and ERGO. The NiNPs/ERGO modified electrode demonstrated excellent square
wave voltammetric response towards ETB determination at the NiNPs/ERGO/GCE in the range 0.05‒100 μM.
The sensor demonstrated outstanding sensitivity towards ETB determination with limit of detection (LOD) and
limit of quantification (LOQ) of 0.023 and 0.075 μM, respectively. The developed sensor was effectively
validated for real sample study using drug formulation and urine samples which showed an acceptable recovery
(99.6‒109%). The electrode also exhibited good precision (RSD < 1%, n = 20), reproducibility (RSD < 1.9%, n =
3), long-term stability (92% of its initial response after two weeks) and selectivity towards interfering substances
in the determination of ethambutol
Framework for Evidence Assessment Based on Grade and Application to HPV Vaccination in Males in the European Health Care Context
n/
Approximate Homomorphisms of Ternary Semigroups
A mapping between ternary semigroups will be
called a ternary homomorphism if . In this paper,
we prove the generalized Hyers--Ulam--Rassias stability of mappings of
commutative semigroups into Banach spaces. In addition, we establish the
superstability of ternary homomorphisms into Banach algebras endowed with
multiplicative norms.Comment: 10 page
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies
PURPOSE: Docosahexaenoic acid-paclitaxel is as an inert prodrug composed
of the natural fatty acid DHA covalently linked to the C2'-position of
paclitaxel (M. O. Bradley et al., Clin. Cancer Res., 7: 3229-3238, 2001).
Here, we examined the role of protein binding as a determinant of the
pharmacokinetic behavior of DHA-paclitaxel. EXPERIMENTAL DESIGN: The blood
distribution of DHA-paclitaxel was studied in vitro using equilibrium
dialysis and in 23 cancer patients receiving the drug as a 2-h i.v.
infusion (dose, 200-1100 mg/m(2)). RESULTS: In vitro, DHA-paclitaxel was
found to bind extensively to human plasma (99.6 +/- 0.057%). The binding
was concentration independent (P = 0.63), indicating a nonspecific,
nonsaturable process. The fraction of unbound paclitaxel increased from
0.052 +/- 0.0018 to 0.055 +/- 0.0036 (relative increase, 6.25%; P = 0.011)
with an increase in DHA-paclitaxel concentration (0-1000 microg/ml),
suggesting weakly competitive drug displacement from protein-binding
sites. The mean (+/- SD) area under the curve of unbound paclitaxel
increased nonlinearly with dose from 0.089 +/- 0.029 microg.h/ml (at 660
mg/m(2)) to 0.624 +/- 0.216 microg.h/ml (at 1100 mg/m(2)), and was
associated with the dose-limiting neutropenia in a maximum-effect model
(R(2) = 0.624). A comparative analysis indicates that exposure to
Cremophor EL and unbound paclitaxel after DHA-paclitaxel (at 1100 mg/m(2))
is similar to that achieved with paclitaxel on clinically relevant dose
schedules. CONCLUSIONS: Extensive binding to plasma proteins may explain,
in part, the unique pharmacokinetic profile of DHA-paclitaxel described
previously with a small volume of distribution ( approximately 4 liters)
and slow systemic clearance ( approximately 0.11 liters/h)
- …